


Figure S1



**Figure S1:** Differential effect of PLX on S1PR expression and cell death in BRAFi-sensitive and BRAFi-resistant cells. (A-B) A375<sup>S</sup> and A375<sup>R</sup> cells were treated or not with PLX (5  $\mu$ M) for 24 (B) or 48 (A) hours in medium containing 7% FBS. (A) Cell viability was assessed using the MTT test. Results are expressed as percentage of the value determined at the corresponding time in the absence of the drug (NT). Data are means  $\pm$  s.e.m. of 3 independent experiments. (B) Cell lysates (30  $\mu$ g of protein) were subjected to SDS-PAGE and immunoblotted with anti-S1PR1, anti-S1PR2, anti-S1PR3 and  $\beta$ -actin antibodies. Left: Representative immunoblot of at least 3 independent experiments. Right: Levels of S1PRs normalized to  $\beta$ -actin and relative to non-treated (NT) cells. (C) WM9<sup>S</sup> and WM9<sup>R</sup> cells were incubated for 48 hours in medium containing 7% FBS in the absence (NT) or presence of PLX (5  $\mu$ M). Cells were labeled with Annexin-V-FITC and propidium iodide, and analyzed by flow cytometry. Percentages (mean  $\pm$  s.e.m. of 3 independent experiments) of Annexin-V-positive cells are indicated. Statistical differences relative to untreated cells are shown (Student's *t*-test). NS, not significant.